Description: Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.
Home Page: www.cardiolrx.com
2265 Upper Middle Road East
Oakville,
ON
L6H 0G5
Canada
Phone:
289-910-0850
Officers
| Name | Title |
|---|---|
| Mr. David G. Elsley MBA | President, CEO & Director |
| Mr. Christopher J. Waddick C.A., C.M.A., CPA, CMA, MBA | CFO, Corporate Secretary & Director |
| Mr. Bernard Lim B.Sc. | Chief Operating Officer |
| Dr. Andrew Warwick Hamer M.D. | Chief Medical Officer & Head of Research & Development |
| Trevor Burns | Investor Relations |
| Mr. John A. Geddes BSCPT, MBA | Vice President of Corporate Development |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 17.7664 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |